COHANCE Q2 FY27 ; CONS NET PROFIT DOWN 79.46% AT ₹15.22 CR (YOY), PROFIT VS LOSS (QOQ)

REVENUE DOWN 14.21% AT ₹476.65 CR (YOY), UP 12.88% (QOQ) EBITDA DOWN 70.75% AT ₹35.38 CR (YOY), UP 2950.00% (QOQ) MARGINS AT 7.42% VS 21.77% (YOY), 0.27% (QOQ)

Cohance Lifesciences Limited

Open attachment

← Back to feed